PBT up 267% to $31.1m as inventory unwind drives $186m cash swing

What changed

Revenue rose 19.0% to NZ$790.6m and EBITDA lifted 43.4% to NZ$68.4m, with operating profit more than doubling to NZ$41.4m. The headline story is below EBITDA: PBT rose 267.3% to NZ$31.1m and NPAT rose 337.9% to NZ$27.9m.

Cash performance was the stand-out. Operating cash flow swung NZ$186.4m, from a NZ$69.1m outflow to a NZ$117.3m inflow. Capex also stepped down to NZ$46.0m from NZ$62.6m, producing a pre-lease FCF of NZ$71.2m versus a NZ$131.7m outflow in HY21. Gross borrowings fell NZ$61.2m to NZ$430.0m, cash rose to NZ$40.6m, and implied net debt fell to NZ$389.4m. Net debt/EBITDA (on half-year EBITDA) improved materially to 5.7x from 10.1x. Segment mix was effectively unchanged, with nutritionals, ingredients and fresh milk at 83.9% of revenue (prior 83.0%) and driving essentially all of the profit recovery (segment result NZ$26.8m vs NZ$4.5m); cheese, butter and yoghurt went the other way (NZ$1.1m vs NZ$1.9m).

What matters

• PBT is the cleaner read, not NPAT. The effective tax rate fell to 10.2% from 24.7%, so NPAT growth of 337.9% overstates the operating recovery. PBT growth of 267.3% is the number to anchor on, and it is still a very large move off a depressed base.
• Working-capital unwind is doing heavy lifting in cash. Inventory fell to NZ$335.6m from NZ$406.4m, with inventory days down roughly 34 to 77.3. Receivable days also fell 9.4 to 24.5. This is consistent with management's stated plan to "release cash from inventory," but the resulting FCF/NPAT ratio of 255% is not a steady-state relationship.
• Leverage direction has reversed, but the level is still high. Net debt/EBITDA at 5.7x on first-half earnings is a material improvement from 10.1x, yet remains elevated in absolute terms. Equity also declined 9.9% year-on-year to NZ$748.0m, so the de-leveraging has come through debt pay-down rather than balance-sheet growth.

Expectations

No quantified guidance, forward-work, or stated profit targets were disclosed in the supplied extracts. Seasonality context is unusually important here because HY21 accounted for 127.9% of FY21 EBITDA, i.e. the H2 FY21 period was EBITDA-negative (implied –NZ$10.4m) and NPAT-negative (implied –NZ$34.8m). On that shape, simply annualising HY22 is unsafe, but HY22 revenue annualised at NZ$1.58b sits about 15.6% above FY21 revenue of NZ$1.37b, consistent with the 19% half-on-half growth.

What the release does support: a clear step-up in profitability versus the HY21 trough and a credible start to the balance-sheet reset. What it does not support: any view on whether H2 FY22 will avoid the sharp sequential fall-off seen in H2 FY21, because no forward-work metric, milk-price assumption, or customer-volume guidance was supplied.

Quality of result

Mixed. The P&L recovery is real but flattered by the tax line; at the operating profit level (up 111.4% to NZ$41.4m) and EBITDA (up 43.4%), the underlying improvement is large but less dramatic than the NPAT headline.

The cash result is substantially timing- and working-capital-driven. Of the NZ$117.3m operating inflow, a large share reflects the inventory reduction of around NZ$70.8m plus lower receivable days. That is a legitimate operating improvement and matches stated strategy, but it cannot repeat at the same magnitude once inventory normalises, so FCF at 255% of NPAT is not a run-rate. Capex also stepped down NZ$16.6m, which helps reported FCF but raises a question on reinvestment intensity.

The segment detail shows the recovery is narrow: nutritionals/ingredients/fresh milk provided essentially all of the year-on-year profit improvement, while the cheese/butter/yoghurt segment went backwards. No non-recurring items were flagged and no EBITDA-to-statutory reconciliation was provided in the excerpts.

Unresolved

• What portion of the NZ$186.4m operating cash swing is durable margin improvement versus a one-time inventory release, and where does a normalised inventory level sit?
• Why did the effective tax rate drop to 10.2%, and is that rate sustainable or a one-period feature?
• What drove the decline in the cheese/butter/yoghurt segment result, and is it cyclical or structural?
• Given the H2 FY21 EBITDA loss, what does management expect for the shape of H2 FY22, and are key customer volumes (notably consumer-packaged infant formula, which was down 16% to 18,085 MT in the prior comparable) stabilising?
• With no declared interim dividend quantified in the extracts, what is the board's capital return posture while net debt/EBITDA remains at 5.7x?

This briefing cannot assess milk-price pass-through, customer concentration, or valuation, because those disclosures were not in the supplied extracts.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.